Skip to main content

Advertisement

Log in

Subclinical activation of lupus nephritis by recombinant human growth hormone

  • Dialysis
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract.

The effect of growth hormone (GH) on subclinical disease activity in a 15-year-old boy with previously quiescent lupus nephritis and chronic renal failure is described. Institution of supraphysiological doses of GH resulted in a rise in erythrocyte sedimentation rate, decrease in serum complement, rise in anti-DNA antibody titers, and increase in T-cell activation markers, all of which improved following cessation of GH treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received April 3, 1997; received in revised form September 2, 1997; accepted September 3, 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yap, HK., Loke, KY., Murugasu, B. et al. Subclinical activation of lupus nephritis by recombinant human growth hormone. Pediatr Nephrol 12, 133–135 (1998). https://doi.org/10.1007/s004670050421

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004670050421

Navigation